GABAB Agonists for the Treatment of Alcohol Use Disorder.

Antonio Mirijello, Fabio Caputo, Gabriele Vassallo, Benjamin Rolland, Claudia Tarli, Antonio Gasbarrini, Giovanni Addolorato

Journal: Current pharmaceutical design 2016;21(23):3367-72

PMID: 26088121

Full Text on Ingenta plc View on PubMed

Abstract

Almost 10% of the world's population is affected by alcohol use disorder (AUD). The combination between psychosocial intervention and pharmacological treatment seems to be the most effective approach for patients affected by AUD. Among effective drugs useful in the treatment of AUD, GABAB-ergic medications have been tested with encouraging results (i.e. sodium oxybate, baclofen, gabapentin, pregabalin and tiagabine). The present review will summarize available data on these medications.

Address: Department of Internal Medicine, Catholic University of Rome, Gemelli Hospital, Largo Gemelli 8, 00168 Rome, Italy. [email protected].

DOI: 10.2174/1381612821666150619091858

Link outs

Free resources

Medical:

https://clinicaltrials.gov/search?term=AREA%5BRefe...

Subscription / membership required

Full Text Sources:

https://www.ingentaconnect.com/openurl?genre=artic...

MeSH Terms: Alcohol-Related Disorders, Brain, GABA-B Receptor Agonists, Humans, Inappropriate Prescribing, Off-Label Use, Patient Safety, Practice Patterns, Physicians', Receptors, GABA-B, Risk Assessment, Risk Factors, Treatment Outcome, gamma-Aminobutyric Acid